2013


To access this material please log in or register

Register Authorize
2013/№2

Nicorandil in correction of coronary reserve and endothelial dysfunction in patients with coronary heart disease

Sizova Zh. M., Zakharova V. L., Shamieva E. S., Kozlova N. V.

Keywords: coronary heart disease, treatment, angina, endothelial dysfunction

DOI: 10.18087/rhj.2013.2.1753

Relevance. Despite of the advantages in drug therapy of CHD, cardiovascular diseases remain major cause of incapacitation and lethality in economically developed countries. In this connection, considerable interest is paid to studying of antianginal efficiency of quite promising modulators (activators) of potassium channels, among which nicorandil is the best-known. Objective. Evaluate antianginal efficiency and safety of nicorandil administration for prevention and relief of angina attacks in CHD patients and its influence on endothelial function. Materials and methods. 67 patients with stable angina FC II–III were enrolled to the study. Patient examination included analysis of heart rate, BP, ECG, exercise tolerance, 24hour Holter monitoring, blood test; Doppler ultrasound of the humeral artery. Results. Nicorandil at treatment of CHD patients with angina FC II–III 20 mg tid within 12 weeks is well tolerable, doesn’t build up tolerance and significantly reduces occurrence rate and duration of angina attacks, occurrence rate and duration of myocardial ischemia events, severity of anginal pain, increases exercise tolerance, improves patients’ quality of life according to a health assessment questionnaire. Endothelium-dependent vasodilation of the humeral artery under the influence of long-term nicorandil therapy is normalized, which is expressed in increase of response to stimulation by the raised blood flow after short-term occlusion by 9,6 % (p<0.001). Conclusion. Nicorandil can be administered for both prevention and relief of angina attacks.
  1. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27 (11):1341–1381.
  2. Шевченко О. П., Мишнев О. Д., Шевченко А. О., Трусов О. А., Сластникова И. Д. Ишемическая болезнь сердца. – М. –Реафарм. 2005. – 416 с.
  3. Ольбинская Л. И., Морозова Т. Е., Сизова Ж. М., Вартанова О. А. и др. Фармакотерапия хронических сердечно-сосудистых заболеваний: Руководство для врачей. – М.: «Медицина», 2006. – 386 с.
  4. Рациональная фармакотерапия сердечно-сосудистых заболеваний: Рук. для практических врачей. Под общ. ред. Е. И. Чазова, Ю. Н. Беленкова. – М.: «Литтерра», 2004. – 972.
  5. Рациональная фармакотерапия сердечно-сосудистых заболеваний: Рук. для практических врачей. Под общ. ред. Е. И. Чазова, Ю. Н. Беленкова. – М.: «Литтерра», 2005. – 972.
  6. Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. Национальные рекомендации ВНОК. Рациональная фармакотерапия в кардиологии 2011; (Приложение 5):24–31
  7. Horinaka S. Use of nicorandil in cardiovascular disease and its optimization. Drugs 2011;71 (9):1105–1119.
  8. Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther. 1990;4 (4):1075–88.
  9. Meany TB, Richardson P, Camm AJ et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol. 1989;63 (21):66J-70J.
  10. Rezkalla SH, Kloner RA. Preconditioning in humans. Heart Fail Rev. 2007;12 (3-4):201–206.
  11. The IONA Study Grup.Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA): randomized trial. Lancet. 2002;359 (9314):1269–1275.
  12. Национальные рекомендации ВНОК. Кардиоваскулярная терапия и профилактика 2011;10 (6); Приложение 2: 57
  13. Japanese Coronary Artery Disease (JCAD) Study Investigators. Current status of the background of patients with coronary artery disease in Japan. Circ J. 2006;70 (10):1256–1262.
  14. Horinaka S, Yabe A, Yagi H et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J. 2010;74 (3):503–509.
  15. Roland E. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. Eur Heart J. 1993;14 (Suppl B): 48–52.
  16. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol. 1989 Jun 20;63 (21):18J-24J.
  17. Cokkinos DV, Pantos C. Myocardial protection in man – from research concept to clinical practice. Heart Fail Rev. 2007;12 (3-4):345–362.
  18. Kitakaze M, Asakura M, Kim J et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370 (9597):1483–1493.
  19. Затейщикова А. А., Затейщиков Д. А. Эндотелиальная регуляция сосудистого тонуса: методы исследования и клиническое значение. Кардиология. 1998;38 (9):69–80.
  20. Ольбинская Л. И., Сизова Ж. М., Ушакова А. В. Эндотелиальная дисфункция у больных ишемической болезнью сердца, осложненной хронической сердечной недостаточность, и возможности коррекции изосорбид-5‑мононитратом. Кардиология. 2001;41 (3):29–32.
  21. Neunteufl T, Heher S, Katzenschlager R et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol. 2000;86 (2):207–210.
  22. Shimbo D, Grahame-Clarke C, Miyake Y et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis. 2007;192 (1):197–203.
Sizova Zh. M., Zakharova V. L., Shamieva E. S. et al. Nicorandil in correction of coronary reserve and endothelial dysfunction in patients with coronary heart disease. Russian Heart Journal. 2013;12(2):75-82

To access this material please log in or register

Register Authorize
Ru En